Drug intelligence / Profile preview

AEX-19

Development stage: Preclinical
Lead developer: Aexon Labs
Modality: Small Molecules
Administration: Oral

Overview

AEX-19 is a small molecule dual agonist of the orexin 1 (OX1R) and orexin 2 (OX2R) receptors, currently in the IND-enabling stage of development by Aexon Labs. The orexin system is a key regulator of sleep-wake cycles, and AEX-19 aims to address conditions characterized by orexin deficiency or impaired signaling. By activating both receptor subtypes, the compound is intended to promote wakefulness and stability of arousal, making it a candidate for the treatment of narcolepsy and other hypersomnia disorders.

Targets

HCRTR2 (Orexin/hypocretin receptor type 2)CTSD (Cathepsin D)HCRTR1 (Orexin/hypocretin receptor type 1)

Beyond the preview

Go deeper on AEX-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEX-19.

Explore the full profile